Richard F Schlenk

List of Publications by Citations

316 papers	16,798 citations	53 h-index	128 g-index
320 ext. papers	19,812 ext. citations	4.8 avg, IF	6.03 L-index

#	Paper	IF	Citations
316	Genomic Classification and Prognosis in Acute Myeloid Leukemia. *New England Journal of Medicine*, **2016**, 374, 2209-2221	59.2	1999
315	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *New England Journal of Medicine*, **2008**, 358, 1909-18	59.2	1330
314	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. *New England Journal of Medicine*, **2017**, 377, 454-464	59.2	1067
313	Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *New England Journal of Medicine*, **2013**, 369, 111-21	59.2	964
312	Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. *New England Journal of Medicine*, **2004**, 350, 1605-16	59.2	822
311	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. *Blood*, **2002**, 100, 4372-80	2.2	690
310	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA - Journal of the American Medical Association*, **2009**, 301, 2349-61	27.4	612
309	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood*, **2012**, 119, 2114-21	2.2	411
308	Targeting FLT3 mutations in AML: review of current knowledge and evidence. *Leukemia*, **2019**, 33, 299-312	10.7	324
307	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. *Blood*, **2011**, 117, 2137-45	2.2	306
306	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. *Nature Reviews Clinical Oncology*, **2012**, 9, 579-90	19.4	303
305	Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. *Journal of Clinical Oncology*, **2011**, 29, 2709-16	2.2	297
304	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. *Blood*, **2011**, 117, 2469-75	2.2	276
303	Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. *Journal of Clinical Oncology*, **2002**, 20, 3254-61	2.2	258
302	RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. *Journal of Clinical Oncology*, **2011**, 29, 1364-72	2.2	245
301	Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. *Blood*, **2006**, 108, 3280-8	2.2	234
300	Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. *Journal of Clinical Oncology*, **2009**, 27, 3994-4001	2.2	230

299	The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. *Cancer*, **2006**, 106, 112-9	6.4	197
298	High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. *Journal of Clinical Oncology*, **2010**, 28, 2101-7	2.2	189
297	How I treat refractory and early relapsed acute myeloid leukemia. *Blood*, **2015**, 126, 319-27	2.2	185
296	Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. *Journal of Clinical Oncology*, **2010**, 28, 4642-8	2.2	178
295	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. *Blood*, **2014**, 124, 1426-33	2.2	172
294	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. *Blood*, **2008**, 111, 1357-65	2.2	170
293	Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *Journal of Clinical Oncology*, **2010**, 28, 3890-8	2.2	167
292	TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. *Journal of Clinical Oncology*, **2012**, 30, 1350-7	2.2	166
291	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. *Haematologica*, **2009**, 94, 54-60	6.6	164
290	Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2006**, 24, 969-75	2.2	157
289	Precision oncology for acute myeloid leukemia using a knowledge bank approach. *Nature Genetics*, **2017**, 49, 332-340	36.3	155
288	The genomic landscape of core-binding factor acute myeloid leukemias. *Nature Genetics*, **2016**, 48, 1551-1556	36.3	147
287	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. *Blood*, **2019**, 133, 840-851	2.2	141
286	Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). *Blood*, **2013**, 121, 170-7	2.2	134
285	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. *Blood*, **2014**, 123, 914-20	2.2	129
284	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). *Blood*, **2013**, 121, 4769-77	2.2	129
283	Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. *Journal of Clinical Oncology*, **2006**, 24, 3887-94	2.2	127
282	Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. *Blood*, **2010**, 115, 636-42	2.2	121

281	Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. *Blood*, **2012**, 119, 551-8	2.2	120
280	The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. *Blood*, **2013**, 122, 1576-82	2.2	115
279	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. *Blood*, **2012**, 120, e83-92	2.2	110
278	Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. *Journal of Clinical Oncology*, **2010**, 28, 3724-9	2.2	110
277	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. *Journal of Clinical Investigation*, **2007**, 117, 1037-48	15.9	100
276	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized	2.2	93
275	Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. *Journal of Clinical Oncology*, **2002**, 20, 2480-5	2.2	87
274	An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. *Blood*, **2008**, 111, 4490-5	2.2	83
273	Precision oncology based on omics data: The NCT Heidelberg experience. *International Journal of Cancer*, **2017**, 141, 877-886	7.5	82
272	Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. *Genes Chromosomes and Cancer*, **2001**, 31, 316-25	5	73
271	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. *British Journal of Haematology*, **2015**, 169, 694-700	4.5	71
270	Post-remission therapy for acute myeloid leukemia. *Haematologica*, **2014**, 99, 1663-70	6.6	69
269	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. *Haematologica*, **2015**, 100, 324-30	6.6	67
268	Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. *Journal of Clinical Oncology*, **2014**, 32, 3406-12	2.2	61
267	Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. *Blood*, **2014**, 123, 4027-36	2.2	60
266	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. *Blood*, **2012**, 119, e67-75	2.2	59
265	Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. *Haematologica*, **2008**, 93, 826-33	6.6	57
264	Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. *Blood*, **2006**, 107, 1242-3	2.2	55

263	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. *Leukemia*, **2018**, 32, 1621-1630	10.7	53
262	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. *Blood*, **2020**, 135, 371-380	2.2	53
261	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. *Annals of Hematology*, **2016**, 95, 1931-1942	3	52
260	Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia. *Haematologica*, **2017**, 102, 2039-2047	6.6	51
259	Management of patients with acute promyelocytic leukemia. *Leukemia*, **2018**, 32, 1277-1294	10.7	50
258	Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. *Leukemia Research*, **2014**, 38, 57-64	2.7	50
257	Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. *Journal of Clinical Oncology*, **2011**, 29, 682-9	2.2	47
256	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. *Blood*, **2019**, 134, 1608-1618	2.2	45
255	Targeted Therapy Alone for Acute Promyelocytic Leukemia. *New England Journal of Medicine*, **2016**, 374, 1197-8	59.2	45
254	Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. *Current Opinion in Hematology*, **2009**, 16, 98-104	3.3	44
253	HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 187-96	4.7	41
252	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. *Haematologica*, **2007**, 92, 763-70	6.6	39
251	Gemtuzumab ozogamicin in acute myeloid leukemia revisited. *Expert Opinion on Biological Therapy*, **2014**, 14, 1185-95	5.4	37
250	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. *Haematologica*, **2011**, 96, 1783-91	6.6	36
249	KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. *British Journal of Haematology*, **2010**, 148, 925-37	4.5	36
248	Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. *British Journal of Haematology*, **1999**, 104, 382-91	4.5	36
247	Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. *Journal of Clinical Oncology*, **2020**, 38, 623-632	2.2	35
246	Minimal residual disease-directed therapy in acute myeloid leukemia. *Blood*, **2015**, 125, 2331-5	2.2	33

245	Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. *Genes Chromosomes and Cancer*, **2005**, 42, 427-32	5	33
244	Therapy-related myeloid neoplasms following treatment with radioiodine. *Haematologica*, **2012**, 97, 206-12	6.6	32
243	The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. *Haematologica*, **2005**, 90, 1626-34	6.6	31
242	Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. *International Journal of Cancer*, **2001**, 93, 80-4	7.5	30
241	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). *Blood*, **2015**, 126, 322-322	2.2	30
240	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. *Blood*, **2020**, 136, 3041-3050	2.2	30
239	Acute myelogenous leukemia in adolescents and young adults. *Pediatric Blood and Cancer*, **2018**, 65, e27089	3	29
238	Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). *Annals of Hematology*, **2012**, 91, 1519-31	3	29
237	PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17). *Clinical Cancer Research*, **2013**, 19, 2562-71	12.9	29
236	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci. *Genes Chromosomes and Cancer*, **2010**, 49, 726-32	5	29
235	Relapsed/refractory acute myeloid leukemia: any progress?. *Current Opinion in Oncology*, **2017**, 29, 467-473	4.2	28
234	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. *Leukemia*, **2020**, 34, 914-918	10.7	26
233	CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. *British Journal of Haematology*, **2004**, 126, 527-35	4.5	25
232	Minimal residual disease in acute myeloid leukemia--current status and future perspectives. *Current Hematologic Malignancy Reports*, **2015**, 10, 132-44	4.4	24
231	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. *Leukemia*, **2020**, 34, 1182-1186	10.7	24
230	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. *Cancer Discovery*, **2021**, 11, 2780-2795	24.4	24
229	Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. *Genes Chromosomes and Cancer*, **2003**, 38, 274-80	5	23
228	Risk-Adapted Therapy in Younger Adults with Acute Myeloid Leukemia: Results of the AMLHD98A Trial of the AMLSG.. *Blood*, **2006**, 108, 14-14	2.2	21

227	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. *Leukemia*, **2021**, 35, 701-711	10.7	21
226	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). *Haematologica*, **2008**, 93, 1219-26	6.6	20
225	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. *Blood*, **2016**, 128, 479-479	2.2	20
224	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. *Nature Medicine*, **2020**, 26, 992-994	50.5	19
223	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. *Blood*, **2021**, 137, 3093-3104	2.2	19
222	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. *Haematologica*, **2016**, 101, 839-45	6.6	19
221	Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. *Epigenetics*, **2016**, 11, 517-25	5.7	18
220	JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. *Haematologica*, **2006**, 91, 1569-70	6.6	18
219	Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. *Leukemia Research*, **2013**, 37, 900-6	2.7	17
218	Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. *British Journal of Haematology*, **2019**, 184, 1018-1021	4.5	16
217	Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. *Journal of Nuclear Medicine*, **2006**, 47, 278-86	8.9	16
216	Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. *Expert Review of Clinical Pharmacology*, **2017**, 10, 1177-1189	3.8	15
215	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. *Blood*, **2016**, 128, 449-449	2.2	15
214	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. *Leukemia*, **2021**, 35, 2539-2551	10.7	15
213	Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. *Haematologica*, **2006**, 91, 285-6	6.6	15
212	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. *Haematologica*, **2020**, 105, 2440-2447	6.6	14
211	Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. *Haematologica*, **2018**, 103, e25-e28	6.6	14
210	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. *Blood*, **2015**, 126, 1669-1669	2.2	14

209	Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series. *Oncologist*, **2021**, 26, 7-16	5.7	14
208	Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. *Leukemia*, **2020**, 34, 2333-2341	10.7	13
207	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. *Blood Advances*, **2020**, 4, 4945-4954	7.8	13
206	Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. *Haematologica*, **2005**, 90, 194-9	6.6	13
205	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. *Haematologica*, **2015**, 100, e122-4	6.6	12
204	Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial. *Blood*, **2018**, 132, 4045-4045	2.2	12
203	Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study). *Blood*, **2018**, 132, 208-208	2.2	12
202	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.. *Blood*, **2005**, 106, 1852-1852	2.2	12
201	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia：Results of the AMLSG 07-04 Randomized Treatment Trial. *Blood* , **2011**, 118, 80-80	2.2	12
200	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. *Blood*, **2012**, 120, 6-6	2.2	12
199	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. *Leukemia and Lymphoma*, **2014**, 55, 2114-9	1.9	11
198	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. *Blood*, **2016**, 128, 589-589	2.2	11
197	A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. *Journal of Medical Internet Research*, **2018**, 20, e10976	7.6	11
196	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. *Blood Advances*, **2020**, 4, 6342-6352	7.8	11
195	Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. *Haematologica*, **2014**, 99, e133-5	6.6	10
194	Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.. *Blood*, **2006**, 108, 4-4	2.2	10
193	Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine. *Blood*, **2010**, 116, 3316-3316	2.2	10
192	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. *Oncotarget*, **2016**, 7, 49539-49551	3.3	10

191	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG). *Blood*, **2016**, 128, 1207-1207	2.2	9
190	CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial. *Blood*, **2016**, 128, 1608-1608	2.2	9
189	Community-driven development of a modified progression-free survival ratio for precision oncology. *ESMO Open*, **2019**, 4, e000583	6	9
188	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. *Leukemia Research*, **2019**, 85, 106197	2.7	8
187	Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials. *Oncology Research and Treatment*, **2007**, 30, 657-62	2.8	8
186	A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis. *Blood*, **2015**, 126, 826-826	2.2	8
185	WhatIs new in consolidation therapy in AML?. *Seminars in Hematology*, **2019**, 56, 96-101	4	8
184	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. *Haematologica*, **2020**, 105, 161-169	6.6	8
183	Is there justification for 4 cycles of consolidation therapy in AML?. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 341-344	4.2	7
182	Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. *Expert Opinion on Biological Therapy*, **2011**, 11, 1369-80	5.4	7
181	The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.. *Blood*, **2007**, 110, 297-297	2.2	7
180	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). *Blood*, **2013**, 122, 527-527	2.2	7
179	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. *Blood*, **2015**, 126, 3744-3744	2.2	7
178	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). *Journal of Clinical Oncology*, **2021**, 39, 3318-3327	2.2	7
177	Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. *Genes Chromosomes and Cancer*, **2011**, 50, 51-8	5	6
176	Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications. *Blood*, **2010**, 116, 909-909	2.2	6
175	Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML. *Blood*, **2011**, 118, 1549-1549	2.2	6
174	Analysis of splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. *Oncotarget*, **2017**, 8, 95163-95175	3.3	6

173	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study. *Haematologica*, **2021**, 106, 3100-3106	6.6	6
172	Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. *Leukemia Research*, **2017**, 62, 84-90	2.7	5
171	Requirement for LIM kinases in acute myeloid leukemia. *Leukemia*, **2020**, 34, 3173-3185	10.7	5
170	MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses. *Haematologica*, **2016**, 101, e454-e456	6.6	5
169	Pathogenic complexity of gastric B-cell lymphoma. *Blood*, **2002**, 100, 1095-6; author reply 1096-7	2.2	5
168	TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG). *Blood*, **2010**, 116, 97-97	2.2	5
167	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. *Blood*, **2014**, 124, 12-12	2.2	5
166	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). *Blood*, **2015**, 126, 609-609	2.2	5
165	Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110). *Blood*, **2016**, 128, 1939-1939	2.2	5
164	Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling. *PLoS ONE*, **2016**, 11, e0155226	3.7	5
163	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. *British Journal of Haematology*, **2019**, 185, 583-587	4.5	5
162	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. *European Journal of Haematology*, **2017**, 99, 544-552	3.8	4
161	Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid. *Haematologica*, **2008**, 93, 1105-7	6.6	4
160	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. *Blood*, **2018**, 132, 720-720	2.2	4
159	Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).. *Blood*, **2009**, 114, 945-945	2.2	4
158	Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653). *Blood*, **2012**, 120, 1483-1483	2.2	4
157	Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML). *Blood* , **2013**, 122, 3756-3756	2.2	4
156	Long-Term Interferon- Treatment in Essential Thrombocythemia. *Blood*, **2015**, 126, 4064-4064	2.2	4

155	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. *Blood*, **2016**, 128, 4271-4271	2.2	4
154	Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. *BMJ Open*, **2020**, 10, e039639	3	4
153	Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. *Haematologica*, **2019**, 104, e63-e64	6.6	4
152	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. *British Journal of Haematology*, **2021**, 192, 832-842	4.5	4
151	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. *Annals of Hematology*, **2017**, 96, 887-894	3	3
150	A new option for remission induction in acute myeloid leukaemia. *Lancet Oncology, The*, **2018**, 19, 156-157	21.7	3
149	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. *Blood*, **2018**, 132, 1501-1501	2.2	3
148	Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease. *Blood*, **2019**, 134, 3928-3928	2.2	3
147	TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome,. *Blood*, **2011**, 118, 3558-3558	2.2	3
146	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. *Blood*, **2018**, 132, 1283-1283	2.2	3
145	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). *Blood*, **2015**, 126, 226-226	2.2	3
144	Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. *Cancer Management and Research*, **2011**, 3, 157-75	3.6	3
143	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.. *Nature Cancer*, **2022**, 3, 251-261	15.4	3
142	Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3-ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.. *Blood*, **2005**, 106, 2353-2353	2.2	2
141	Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups.. *Blood*, **2005**, 106, 2360-2360	2.2	2
140	Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG.. *Blood*, **2005**, 106, 2800-2800	2.2	2
139	Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup.. *Blood*, **2006**, 108, 16-16	2.2	2
138	Impact of Pegfilgrastim on Hematological Reconstitution and Incidence of Neutropenic Fever after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukemia: Comparative Analysis between AMLSG 07-04 and the German AML Intergroup Trial.. *Blood*, **2006**, 108, 2020-2020	2.2	2

137	Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG).. *Blood*, **2007**, 110, 364-364	2.2	2
136	Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy.. *Blood*, **2008**, 112, 1953-1953	2.2	2
135	Role of Etoposide in Combination with All-Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation. *Blood*, **2008**, 112, 559-559	2.2	2
134	In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.. *Blood*, **2009**, 114, 2632-2632	2.2	2
133	Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).. *Blood*, **2009**, 114, 824-824	2.2	2
132	A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML. *Blood*, **2010**, 116, 3285-3285	2.2	2
131	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia. *Blood*, **2011**, 118, 423-423	2.2	2
130	CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study. *Blood*, **2012**, 120, 3816-3816	2.2	2
129	Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response □ Evolutionary -, and Remission Patterns and No Increased Karyotype Evolution (KE). *Blood*, **2013**, 122, 2783-2783	2.2	2
128	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). *Blood*, **2014**, 124, 1992-1992	2.2	2
127	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. *Blood*, **2015**, 126, 803-803	2.2	2
126	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). *Blood*, **2016**, 128, 112-112	2.2	2
125	Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia.. *Blood*, **2006**, 108, 8-8	2.2	2
124	Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid Leukemia (AML). *Blood*, **2013**, 122, 2539-2539	2.2	2
123	Adjusting Simonls optimal two-stage design for heterogeneous populations based on stratification or using historical controls. *Biometrical Journal*, **2020**, 62, 311-329	1.5	2
122	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). *British Journal of Haematology*, **2018**, 183, 235-241	4.5	2
121	Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. *Blood*, **2019**, 134, 2693-2693	2.2	1
120	Characterization of NPM1-Mutated/FLT3 ITD-Negative Acute Myeloid Leukemia with Normal Karyotype by Gene Expression Profiling.. *Blood*, **2006**, 108, 155-155	2.2	1

119	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. *Blood*, **2007**, 110, 1806-1806	2.2	1
118	CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations.. *Blood*, **2007**, 110, 363-363	2.2	1
117	Combined Analysis of Valproic Acid Induced MicroRNA and Gene Expression Changes in Acute Myeloid Leukemia.. *Blood*, **2007**, 110, 869-869	2.2	1
116	RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG). *Blood*, **2008**, 112, 145-145	2.2	1
115	Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG.. *Blood*, **2009**, 114, 1600-1600	2.2	1
114	Mutations of EZH2 In Myeloproliferative Neoplasms with Myelofibrosis: Correlation with Molecular and Clinical Data. *Blood*, **2010**, 116, 4111-4111	2.2	1
113	ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG. *Blood*, **2011**, 118, 412-412	2.2	1
112	DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG. *Blood*, **2011**, 118, 415-415	2.2	1
111	Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322). *Blood*, **2012**, 120, 412-412	2.2	1
110	Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study. *Blood*, **2013**, 122, 4064-4064	2.2	1
109	Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 1381-1381	2.2	1
108	Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG). *Blood*, **2015**, 126, 2585-2585	2.2	1
107	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 2586-2586	2.2	1
106	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. *Blood*, **2015**, 126, 2891-2891	2.2	1
105	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. *Blood*, **2015**, 126, 85-85	2.2	1
104	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. *Blood*, **2016**, 128, 337-337	2.2	1
103	Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.. *Blood*, **2006**, 108, 2301-2301	2.2	1
102	RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.. *Blood*, **2006**, 108, 2303-2303	2.2	1

101	Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.. *Blood*, **2007**, 110, 759-759	2.2	1
100	A Multicenter Phase-Ib/II Study of Ruxolitinib/Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis: Safety Data from the Mpnsg-0212 Trial (NCT01644110). *Blood*, **2014**, 124, 3161-3161	2.2	1
99	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. *Blood*, **2016**, 128, 2815-2815	2.2	1
98	Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients. *Blood*, **2008**, 112, 2641-2641	2.2	1
97	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. *Blood*, **2008**, 112, 2973-2973	2.2	1
96	Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).. *Blood*, **2009**, 114, 825-825	2.2	1
95	AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms. *Blood*, **2010**, 116, 291-291	2.2	1
94	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with -mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. *Haematologica*, **2021**, 106, 2986-2989	6.6	1
93	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. *Blood Advances*, **2021**, 5, 4370-4379	7.8	1
92	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG). *Blood*, **2015**, 126, 3818-3818	2.2	0
91	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. *Blood*, **2021**, 138, 692-692	2.2	0
90	Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status. *Blood*, **2021**, 138, 2380-2380	2.2	0
89	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. *Blood*, **2021**, 138, 4418-4418	2.2	0
88	NF1 Alterations Are Common In AML with Complex Karyotype and Correlate with Specific Genomic Imbalances. *Blood*, **2010**, 116, 4179-4179	2.2	0
87	Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. *Journal of Medical Genetics*, **2017**, 54, 640-650	5.8	
86	Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease. *Blood*, **2021**, 138, 3404-3404	2.2	
85	Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4. *Blood*, **2021**, 138, 1307-1307	2.2	
84	Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition. *Blood*, **2021**, 138, 3469-3469	2.2	

83	MLL/AF9 Fusion Transcript Quantification in t(9;11)-Positive AML Identify Patients with High Risk of Relapse.. *Blood*, **2004**, 104, 3015-3015	2.2
82	Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling.. *Blood*, **2004**, 104, 2037-2037	2.2
81	Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.. *Blood*, **2004**, 104, 2896-2896	2.2
80	Pooled Data Analysis of Acute Myeloid Leukemia Patients <= 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.. *Blood*, **2005**, 106, 2374-2374	2.2
79	Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.. *Blood*, **2005**, 106, 747-747	2.2
78	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. *Blood*, **2005**, 106, 1849-1849	2.2
77	Prognostic Gene-Expression Signatures in Adult Acute Myeloid Leukemia with Normal Karyotype.. *Blood*, **2005**, 106, 756-756	2.2
76	Pretreatment Cytogenetic Abnormalities Are Predictive of Induction Success, Cumulative Incidence of Relapse and Overall Survival in Patients >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia.. *Blood*, **2005**, 106, 3293-3293	2.2
75	Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).. *Blood*, **2005**, 106, 1138-1138	2.2
74	Gene Expression Profiling Identifies Distinct Subclasses in Core Binding Factor Acute Myeloid Leukemia.. *Blood*, **2005**, 106, 673-673	2.2
73	Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.. *Blood*, **2005**, 106, 2352-2352	2.2
72	A FLT3 Gene-Expression Signature Outperforms FLT3 Status in Predicting Clinical Outcome for Patients with Normal Karyotype AML.. *Blood*, **2006**, 108, 2311-2311	2.2
71	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. *Blood*, **2006**, 108, 1949-1949	2.2
70	Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.. *Blood*, **2006**, 108, 414-414	2.2
69	In Vitro and In Vivo Monitoring of Valproic Acid Effects on Gene Expression Signatures in Adult Acute Myeloid Leukemia.. *Blood*, **2006**, 108, 2605-2605	2.2
68	Minimal Residual Disease (MRD) Monitoring in CBFB-MYH11 Acute Myeloid Leukemia (AML) Is of Prognostic Relevance for Relapse-Free Survival.. *Blood*, **2006**, 108, 2298-2298	2.2
67	Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.. *Blood*, **2007**, 110, 3485-3485	2.2
66	Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia.. *Blood*, **2007**, 110, 1446-1446	2.2

65	Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial.. *Blood*, **2007**, 110, 1836-1836	2.2
64	Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).. *Blood*, **2007**, 110, 762-762	2.2
63	KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.. *Blood*, **2007**, 110, 3163-3163	2.2
62	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.. *Blood*, **2007**, 110, 1837-1837	2.2
61	The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.. *Blood*, **2007**, 110, 881-881	2.2
60	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide an International Collaborative Study. *Blood*, **2018**, 132, 80-80	2.2
59	The Genes for Tissue Factor F3 and Nuclear Receptor 4A Are Down-Regulated in Early Death Acute Promyelocytic Leukemia Patients. *Blood*, **2018**, 132, 3902-3902	2.2
58	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG). *Blood*, **2019**, 134, 2740-2740	2.2
57	Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network. *Blood*, **2019**, 134, 2998-2998	2.2
56	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). *Blood*, **2014**, 124, 1254-1254	2.2
55	ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance?. *Blood*, **2014**, 124, 3618-3618	2.2
54	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts . *Blood*, **2014**, 124, 2636-2636	2.2
53	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Getlam and Acute Leukemia Working Party of EBMT. *Blood*, **2014**, 124, 324-324	2.2
52	A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial. *Blood*, **2014**, 124, 1918-1918	2.2
51	NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia. *Blood*, **2014**, 124, 2338-2338	2.2
50	Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial. *Blood*, **2014**, 124, 1920-1920	2.2
49	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. *Blood*, **2015**, 126, 2553-2553	2.2
48	Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome. *Blood*, **2015**, 126, 4123-4123	2.2

47	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. *Blood*, **2015**, 126, 224-224	2.2
46	Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 3844-3844	2.2
45	Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome. *Blood*, **2015**, 126, 5523-5523	2.2
44	Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG). *Blood*, **2015**, 126, 227-227	2.2
43	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA). *Blood*, **2016**, 128, 4038-4038	2.2
42	Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449).. *Journal of Clinical Oncology*, **2017**, 35, 2056-2056	2.2
41	Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1. *Blood*, **2008**, 112, 2514-2514	2.2
40	Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.. *Blood*, **2008**, 112, 1487-1487	2.2
39	Distinct Expression Patterns in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Characterized by Uniparental Disomy.. *Blood*, **2008**, 112, 1193-1193	2.2
38	Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG). *Blood*, **2008**, 112, 699-699	2.2
37	Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. *Blood*, **2009**, 114, 578-578	2.2
36	High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.. *Blood*, **2009**, 114, 582-582	2.2
35	Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. *Blood*, **2009**, 114, 2621-2621	2.2
34	Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).. *Blood*, **2009**, 114, 1586-1586	2.2
33	Deregulated Apoptotic Pathways Point to Effectiveness of IAP Inhibitor Therapy in Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 1275-1275	2.2
32	Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.. *Blood*, **2009**, 114, 2391-2391	2.2
31	Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML.. *Blood*, **2009**, 114, 2613-2613	2.2
30	Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study. *Blood*, **2010**, 116, 185-185	2.2

29	Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. *Blood*, **2010**, 116, 2184-2184	2.2
28	A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML). *Blood*, **2010**, 116, 3310-3310	2.2
27	Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG). *Blood*, **2010**, 116, 101-101	2.2
26	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. *Blood*, **2010**, 116, 849-849	2.2
25	Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup. *Blood*, **2010**, 116, 2175-2175	2.2
24	Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia. *Blood*, **2010**, 116, 3297-3297	2.2
23	Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification. *Blood*, **2010**, 116, 1693-1693	2.2
22	Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples. *Blood*, **2011**, 118, 237-237	2.2
21	Integrative Genomics Approaches Identify Novel Disease-Related Genetic Aberrations in Acute Myeloid Leukemia. *Blood*, **2011**, 118, 402-402	2.2
20	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. *Blood*, **2011**, 118, 1533-1533	2.2
19	Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations,. *Blood*, **2011**, 118, 3546-3546	2.2
18	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. *Blood*, **2011**, 118, 1441-1441	2.2
17	Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. *Blood*, **2012**, 120, 3801-3801	2.2
16	Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems. *Blood*, **2012**, 120, 734-734	2.2
15	Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01□9 Study (ClinicalTrials.gov Identifier: NCT00949364).. *Blood*, **2012**, 120, 2840-2840	2.2
14	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. *Blood*, **2012**, 120, 46-46	2.2
13	Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. *Blood*, **2012**, 120, 785-785	2.2
12	The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 2563-2563	2.2

List of Publications

11	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. *Blood*, **2013**, 122, 2555-2555	2.2
10	Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 830-830	2.2
9	Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). *Blood*, **2013**, 122, 3878-3878	2.2
8	An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1. *Blood*, **2013**, 122, 2593-2593	2.2
7	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG). *Blood*, **2013**, 122, 1332-1332	2.2
6	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 1314-1314	2.2
5	Pomalidomide In MPN‐associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study. *Blood*, **2013**, 122, 2822-2822	2.2
4	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. *Blood*, **2013**, 122, 2759-2759	2.2
3	Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study. *Blood*, **2013**, 122, 3927-3927	2.2
2	Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). *Annals of Hematology*, **2021**, 100, 1463-1471	3
1	Ruxolitinib is effective in the treatment of a patient with refractory T-ALL. *EJHaem*, **2021**, 2, 139-142	0.9